128 related articles for article (PubMed ID: 38106767)
1. An Evaluation of the Appropriateness of Initial Enoxaparin Dosing Among Pediatric Patients.
Altuwayjiri A; AlDarwish A; Alshuraim R
Cureus; 2023 Nov; 15(11):e48830. PubMed ID: 38106767
[TBL] [Abstract][Full Text] [Related]
2. Effects of age and weight-based dosing of enoxaparin on anti-factor xa levels in pediatric patients.
Fung LS; Klockau C
J Pediatr Pharmacol Ther; 2010 Apr; 15(2):119-25. PubMed ID: 22477802
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of an enoxaparin dosing calculator using burn size and weight.
Faraklas I; Ghanem M; Brown A; Cochran A
J Burn Care Res; 2013; 34(6):621-7. PubMed ID: 24043245
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
Lim W; Dentali F; Eikelboom JW; Crowther MA
Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
[TBL] [Abstract][Full Text] [Related]
5. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
[TBL] [Abstract][Full Text] [Related]
6. Anti-Xa guided enoxaparin dose adjustment improves pharmacologic deep venous thrombosis prophylaxis in burn patients.
Cronin BJ; Godat LN; Berndtson AE; Pham A; Kolan S; Box K; Lee JG; Costantini TW
Burns; 2019 Jun; 45(4):818-824. PubMed ID: 30827851
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a Pediatric Enoxaparin Dosing Protocol and the Impact on Clinical Outcomes.
Wiltrout K; Lissick J; Raschka M; Nickel A; Watson D
J Pediatr Pharmacol Ther; 2020; 25(8):689-696. PubMed ID: 33214779
[TBL] [Abstract][Full Text] [Related]
8. Retrospective comparison of two enoxaparin dosing and monitoring protocols at a pediatric hospital.
Wolsey A; Wilcox RA; Olson JA; Boehme S; Anderson CR
Am J Health Syst Pharm; 2019 May; 76(11):815-819. PubMed ID: 31361813
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels.
Bauman ME; Belletrutti MJ; Bajzar L; Black KL; Kuhle S; Bauman ML; Patricia Massicotte M
Thromb Haemost; 2009 Jan; 101(1):86-92. PubMed ID: 19132193
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Initial Enoxaparin Dosing and Antifactor Xa Levels in Infants Admitted to the Neonatal Intensive Care Unit.
Nagy R; Hemmelgarn T; Deptola S; Hemmann B
Biomed Hub; 2024; 9(1):54-61. PubMed ID: 38616894
[TBL] [Abstract][Full Text] [Related]
11. Creatinine Clearance May Predict Goal Enoxaparin Dose in Trauma.
Park G; Dhillon NK; Fierro NM; Drevets P; Stupinski J; Ley EJ
J Am Coll Surg; 2023 Jul; 237(1):94-100. PubMed ID: 36942874
[TBL] [Abstract][Full Text] [Related]
12. Achievement of goal anti-Xa activity with weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients.
Taylor A; Huang E; Waller J; White C; Martinez-Quinones P; Robinson T
Pharmacotherapy; 2021 Jun; 41(6):508-514. PubMed ID: 33864688
[TBL] [Abstract][Full Text] [Related]
13. A Critical Evaluation of Enoxaparin Dose Adjustment Guidelines in Children.
Dinh CN; Moffett BS; Galati M; Lee-Kim Y; Yee DL; Mahoney D
J Pediatr Pharmacol Ther; 2019; 24(2):128-133. PubMed ID: 31019405
[TBL] [Abstract][Full Text] [Related]
14. Anti-Xa-guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients.
Singer GA; Riggi G; Karcutskie CA; Vaghaiwalla TM; Lieberman HM; Ginzburg E; Namias N; Lineen EB
J Trauma Acute Care Surg; 2016 Dec; 81(6):1101-1108. PubMed ID: 27488490
[TBL] [Abstract][Full Text] [Related]
15. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
[TBL] [Abstract][Full Text] [Related]
16. Can we reliably predict the level of anticoagulation after enoxaparin injection in elderly patients with renal failure?
Pellizzari L; Facchinetti R; Corrà L; Sepe A; Fantin F; Fontana G; Zamboni M; Di Francesco V
Aging Clin Exp Res; 2018 Jun; 30(6):605-608. PubMed ID: 28808989
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of Enoxaparin in Pediatric Patients.
Moffett BS; Lee-Kim Y; Galati M; Mahoney D; Shah MD; Teruya J; Yee D
Ann Pharmacother; 2018 Feb; 52(2):140-146. PubMed ID: 28962537
[TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Enoxaparin Dosing and Monitoring in Pediatric Patients at Children's Teaching Hospital.
McCormick EW; Parbuoni KA; Huynh D; Morgan JA
J Pediatr Pharmacol Ther; 2015; 20(1):33-6. PubMed ID: 25859168
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.
Sofjan AK; Iuppa JA; Bain KB; Deal EN; Witt CA; Hachem RR; Yusen RD
Ann Pharmacother; 2016 Oct; 50(10):824-31. PubMed ID: 27363845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
